Syneos Health, Inc. (SYNH)
| Market Cap | 8.67B |
| Revenue (ttm) | 4.46B |
| Net Income (ttm) | 197.94M |
| Shares Out | 104.27M |
| EPS (ttm) | 1.88 |
| PE Ratio | 43.96 |
| Forward PE | 19.23 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 10 |
| Last Price | $82.64 |
| Previous Close | $82.82 |
| Change ($) | -0.18 |
| Change (%) | -0.22% |
| Day's Open | 83.06 |
| Day's Range | 82.34 - 84.01 |
| Day's Volume | 1,220,436 |
| 52-Week Range | 50.26 - 89.95 |
MORRISVILLE, N.C., May 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization, today annou...
MORRISVILLE, N.C., May 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization, today annou...
Syneos Health (SYNH) registers sales uptick in its Clinical Solutions business on the back of favorable acquisition impacts and increased project start-up activities.
MORRISVILLE, N.C., April 30, 2021 (GLOBE NEWSWIRE) -- The Illingworth Research Group, a Syneos Health® company, has been recognized with a 2021 Queen's Award for Enterprise for International Trade. Illi...
Syneos Health (SYNH) delivered earnings and revenue surprises of 6.76% and 1.83%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Syneos Health (NASDAQ:SYNH) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share increased 16.18% over the past year to $0.79, which beat the estimat...
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MORRISVILLE, N.C., April 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its first quarter 2021 financial resu...
Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery of its operating segments and strategic partnerships.
Syneos Health (SYNH) new partnership will extend the company's mission to boost research and enable universal patient and provider access with clinical research services.
Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock?
MORRISVILLE, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining ...
MORRISVILLE, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining ...
Strategic Partnership Optimizes Integration for EHR Data and Delivers Remote Source Data Review Strategic Partnership Optimizes Integration for EHR Data and Delivers Remote Source Data Review
Seasoned Talent to Drive Expansion of Solutions at the Intersection of Value and Policy Seasoned Talent to Drive Expansion of Solutions at the Intersection of Value and Policy
Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.
Syneos Health (SYNH) delivered earnings and revenue surprises of 0.00% and 0.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Syneos Health (NASDAQ:SYNH) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share rose 7.77% year over year to $1.11, which beat the estimate of $1.10.
Shared Commitment to Change, New Prescriber Realities, Model Evolution and Engagement Transformation Expected to be Critical Drivers Shared Commitment to Change, New Prescriber Realities, Model Evolutio...
MORRISVILLE, N.C., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its fourth quarter and full year 2020 ...
MORRISVILLE, N.C., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and...
Syneos Health (SYNH) is currently working on bringing greater flexibility to each customer study, based on data, people, process and technology.
Acquisition Enhances Company's Decentralized Solutions Offering by Strengthening Patient Focus Acquisition Enhances Company's Decentralized Solutions Offering by Strengthening Patient Focus
As of late, it has definitely been a great time to be an investor in Syneos Health (SYNH).
Let's see if Syneos Health (SYNH) stock is a good choice for value-oriented investors right now from multiple angles.
Syneos Health reduced its 2020 guidance but boosted its EBITDA margin guidance.
GREENWICH, Conn.--(BUSINESS WIRE)--Amulet Capital Partners Completes the Sale of Synteract to Syneos Health
MORRISVILLE, N.C., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it has completed the previousl...
Unique Product Development Model Delivers Accelerated Growth
CAMBRIDGE, Mass. & MORRISVILLE, N.C.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company developing next-generation infectious disease and immuno-oncology vac...
Combination Offers Customers Access to Largest U.S. Oncology Real World Data Source and Best-in-Class Product Development Expertise for Faster, Smarter and More Patient-Centric Clinical Trials Combinati...
MORRISVILLE, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a...
MORRISVILLE, N.C., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a...
Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery in the Clinical Solutions segment and strategic partnerships.
MORRISVILLE, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a...
MORRISVILLE, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a...
MORRISVILLE, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a...
MORRISVILLE, N.C., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of Larry A. Pickett,...
MORRISVILLE, N.C., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and...
Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.
MORRISVILLE, N.C., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and...
Syneos Health, Inc. (SYNH) CEO Alistair Macdonald on Q3 2020 Results - Earnings Call Transcript
Shares of Syneos Health (NASDAQ:SYNH) moved higher by 3.2% in pre-market trading after the company reported Q3 results.
Syneos Health (SYNH) delivered earnings and revenue surprises of 15.56% and -1.92%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
GREENWICH, Conn.--(BUSINESS WIRE)--Amulet Capital Backed Synteract To Be Acquired by Syneos Health
Combination Enhances Syneos Health's Industry-Leading Position Across Fast-Growing Small to Mid-Sized Category Combination Enhances Syneos Health's Industry-Leading Position Across Fast-Growing Small to...
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About SYNH
Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist c... [Read more...]
| Industry Diagnostics & Research | IPO Date Nov 7, 2014 |
| CEO Alistair Macdonald | Employees 24,310 |
| Stock Exchange NASDAQ | Ticker Symbol SYNH |
Financial Performance
In 2020, Syneos Health's revenue was $4.42 billion, a decrease of -5.56% compared to the previous year's $4.68 billion. Earnings were $192.79 million, an increase of 46.88%.
Analyst Forecasts
According to 14 analysts, the average rating for Syneos Health stock is "Buy." The 12-month stock price forecast is 94.55, which is an increase of 14.41% from the latest price.